Get the Stockscreener App
6.62
15.13%
-1.18
After Hours:
6.91
0.29
+4.38%
Eyepoint Pharmaceuticals Inc stock is traded at $6.62, with a volume of 1.69M.
It is down -15.13% in the last 24 hours and down -23.73% over the past month.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
See More
Previous Close:
$7.80
Open:
$7.81
24h Volume:
1.69M
Relative Volume:
2.00
Market Cap:
$451.82M
Revenue:
$46.02M
Net Income/Loss:
$-70.80M
P/E Ratio:
-3.6374
EPS:
-1.82
Net Cash Flow:
$-1.61M
1W Performance:
-17.76%
1M Performance:
-23.73%
6M Performance:
-26.61%
1Y Performance:
-77.07%
1-Day Range:
$6.60
$7.82
1-Week Range:
$6.55
$8.68
52-Week Range:
$6.55
$30.99
Eyepoint Pharmaceuticals Inc Stock (EYPT) Company Profile
Name
Eyepoint Pharmaceuticals Inc
Sector
Industry
Phone
617-926-5000
Address
480 PLEASANT STREET, WATERTOWN, MA
Compare EYPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Pharmaceuticals Inc
|
6.62 | 451.82M | 46.02M | -70.80M | -1.61M | -1.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Eyepoint Pharmaceuticals Inc Stock (EYPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-25 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-28-24 | Initiated | Jefferies | Buy |
| Jan-22-24 | Initiated | JP Morgan | Overweight |
| Nov-02-23 | Initiated | Mizuho | Buy |
| Apr-21-23 | Initiated | Robert W. Baird | Outperform |
| Jul-07-22 | Initiated | Chardan Capital Markets | Buy |
| Mar-01-21 | Initiated | Cowen | Outperform |
| Jan-28-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Nov-04-19 | Resumed | Laidlaw | Buy |
| Sep-12-19 | Initiated | Guggenheim | Buy |
View All
Eyepoint Pharmaceuticals Inc Stock (EYPT) Latest News
Investors unsure on EyePoint’s Duravyu blockbuster claim - The Pharma Letter
A significant driver of top-line growth: EyePoint Pharmaceuticals Inc (EYPT) - SETE News
EyePoint Pharmaceuticals (NASDAQ:EYPT) Reaches New 1-Year LowHere's What Happened - MarketBeat
There Is A Lot Of Upside Potential For EyePoint Pharmaceuticals Inc(NASDAQ: EYPT) - Stocks Register
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Recommendation of “Buy” by Analysts - ETF Daily News
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of "Buy" by Analysts - MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of “Buy” by Analysts - Defense World
EyePoint's decline following positive data makes no sense, says analyst - MSN
EyePoint stock jumps 10% on Duravyu study results - MSN
(EYPT) Investment Analysis - Stock Traders Daily
Analyzing the Impact of Earnings Reports on EyePoint Pharmaceuticals Inc Inc. (EYPT) Price Performance - The InvestChronicle
TD Cowen maintains EyePoint stock Buy rating, $20 target - Investing.com India
Short Interest in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Rises By 9.9% - MarketBeat
EyePoint Pharmaceuticals : Investor Presentation February 2025 - Marketscreener.com
EyePoint stock jumps 10% on Duravyu study results (EYPT:NASDAQ) - Seeking Alpha
EyePoint's Phase 2 Trial of Duravyu to Treat Diabetic Macular Edema Meets Endpoints; Shares Still Slump Pre-Bell - Marketscreener.com
EyePoint's decline following positive data makes no sense, says analyst By Investing.com - Investing.com South Africa
Collegium Appoints Nancy S. Lurker to its Board of Directors - The Manila Times
Pharma Veteran Nancy Lurker Joins Collegium Board: Ex-Novartis CMO Brings M&A Expertise - StockTitan
EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema Meeting Primary and Secondary Endpoints - The Manila Times
EyePoint Pharmaceuticals stock sinks following clinical trial results By Investing.com - Investing.com South Africa
Should investors be concerned about EyePoint Pharmaceuticals Inc (EYPT)? - US Post News
EyePoint Pharmaceuticals stock sinks following clinical trial results - Investing.com
Clinical Trial Success: EyePoint's DME Drug Reduces Treatment Burden by Two-Thirds - StockTitan
Analyzing EyePoint Pharmaceuticals Inc (EYPT) After Recent Trading Activity - Knox Daily
Financial Health Report: EyePoint Pharmaceuticals Inc (EYPT)’s Ratios Tell a Tale - The Dwinnex
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Short Interest Update - Defense World
EyePoint: A Risky 'Buy' Ahead Of Key Readout For Long-Acting Eylea Rival (NASDAQ:EYPT) - Seeking Alpha
EyePoint Pharmaceuticals' CEO Jay S. Duker to Speak at Guggenheim SMID Cap Biotech Conference on February 6, 2025 - Nasdaq
EyePoint to Present at Guggenheim SMID Cap Biotech Conference - The Manila Times
Inside EyePoint's Strategy: CEO Set to Reveal Latest Developments in Retinal Disease Treatment - StockTitan
Franklin Resources Inc. Expands Portfolio with EyePoint Pharmace - GuruFocus.com
Long Term Trading Analysis for (EYPT) - Stock Traders Daily
Strong week for EyePoint Pharmaceuticals (NASDAQ:EYPT) shareholders doesn't alleviate pain of one-year loss - Yahoo Finance
Brokers Offer Predictions for EYPT FY2025 Earnings - Defense World
EyePoint Pharmaceuticals (NASDAQ:EYPT) Trading 6.1% HigherShould You Buy? - MarketBeat
Research Analysts Issue Forecasts for EYPT FY2025 Earnings - MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Short Interest Up 9.9% in December - MarketBeat
JPMorgan Chase & Co. Purchases 342,516 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - MarketBeat
JPMorgan Chase & Co. Raises Stock Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
EyePoint Pharmaceuticals (NASDAQ:EYPT) Trading Up 3.4%Here's What Happened - MarketBeat
Further weakness as EyePoint Pharmaceuticals (NASDAQ:EYPT) drops 20% this week, taking one-year losses to 68% - Simply Wall St
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
EyePoint Pharmaceuticals Awards Stock Options to New Employees in Retention Move - StockTitan
(EYPT) Trading Signals - Stock Traders Daily
EyePoint reports progress in DURAVYU AMD trials By Investing.com - Investing.com Canada
EyePoint reports progress in DURAVYU AMD trials - Investing.com India
EYPTEyePoint Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
EyePoint's DURAVYU Shows Strong DME Trial Results, Reports $370M Cash Position for 2025 - StockTitan
Brokerages Set EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) PT at $26.63 - MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Rating of “Buy” from Analysts - Defense World
Eyepoint Pharmaceuticals Inc Stock (EYPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):